DataString Consulting Company Logo
DataString Consulting Company Logo
Sevelamer Hydrochloride Tablet Market
Home»Recent Reports»Sevelamer Hydrochloride Tablet Market

Sevelamer Hydrochloride Tablet Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802530, Published - June 2025

Segmented in Dosage Form (Capsule, Liquid), End-Use Industries (Healthcare Providers, Retail Pharmacies, Online Pharmacies, Geriatric Care Centers, Chronic Kidney Disease Clinics, Others), Therapy Area, Prescription Category, Distribution Channels and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Sevelamer Hydrochloride Tablet
Market Outlook

The market, for Sevelamer Hydrochloride Tablet was estimated at $965.5 million in 2024; and it is anticipated to increase to $1.4 billion by 2030 with projections indicating a growth to around $1.9 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.4% over the forecast period. The strong growth reflects the need for SEVELAMER HYDROCHLORIDE tablets in the worldwide pharmaceutical market. This key medicine plays a role in treating issues like hyperphosphatemia seen in individuals undergoing dialysis. The increase in cases of kidney disease and the rise, in dialysis treatments globally have fueled this growing pattern, which has also reinforced the market standing of SEVELAMER HYDROCHLORIDE tablets. The latest progress in producing pharmaceuticals and the growth of healthcare spending in developing countries are driving up the demand, for this product.


The SEVELAMER HYDROCHLORIDE pill is a binder taken by mouth that helps the body reduce the intake of phosphate from food sources to preserve electrolyte balance in individuals undergoing dialysis treatment by managing high serum phosphate levels effectively and offering notable therapeutic advantages when combined with other therapies, for end stage renal disease patients.


Market Size Forecast & Key Insights

2019
$965M2024
2029
$1.8B2034

Absolute Growth Opportunity = $830M

The Sevelamer Hydrochloride Tablet market is projected to grow from $965.5 million in 2024 to $1.80 billion in 2034. This represents a CAGR of 6.4%, reflecting rising demand across Medical Treatment for Chronic Kidney Disease (CKD), Management of Hyperphosphatemia and Dialysis Treatment.

The Sevelamer Hydrochloride Tablet market is set to add $830 million between 2024 and 2034, with manufacturer targeting Retail Pharmacies & Online Pharmacies End-Use Industries projected to gain a larger market share.

With Rising prevalence of kidney disorders, and Growing awareness about effective treatment options, Sevelamer Hydrochloride Tablet market to expand 86% between 2024 and 2034.

Opportunities in the Sevelamer Hydrochloride Tablet Market

Niche Audience Engagement

With the increase in awareness about health and the growing number of people suffering from kidney issues worldwide; there is a predicted substantial growth in the demand for SEVELAMER HYDROCHLORIDE tablets for treating hyperphosphatemia in patients with kidney diseases. The current use of these tablets is mainly seen among groups of people. Thus exploring market segments through customized marketing approaches could lead to promising business expansion opportunities. Customers with dietary habits, lifestyles and preferences highlight the necessity for tailor made therapies, for managing kidney diseases more effectively.

Growth Opportunities in North America and Asia Pacific

Asia Pacific Outlook

The Asia Pacific region is an emerging market for SEVELAMER HYDROCHLORIDE tablet. With large untapped demographic advantage and expanding healthcare facilities, countries like India and China are driving the demand for these tablets. The battle against chronic kidney diseases amidst a population well above 1 billion is further bolstering opportunities for the SEVELAMER HYDROCHLORIDE market. The region lags due to the underdeveloped healthcare infrastructure and challenges over affordability.

North America Outlook

North America showcases a vast potential for the growth of SEVELAMER HYDROCHLORIDE tablet market. With rising geriatric population and increased incidences of chronic kidney diseases, the demand for SEVELAMER HYDROCHLORIDE tablets, a renowned phosphate binder, has seen a considerable hike. The US, being the advanced healthcare market and innovation hub, dominates the region with increased acceptance of preventive healthcare and Medicare services, which promote the use of SEVELAMER HYDROCHLORIDE tablet. Nonetheless, the market here faces stiff competition, primarily owing to the existence of other established phosphate binders and novel therapeutics in kidney care.

North America Outlook

North America showcases a vast potential for the growth of SEVELAMER HYDROCHLORIDE tablet market. With rising geriatric population and increased incidences of chronic kidney diseases, the demand for SEVELAMER HYDROCHLORIDE tablets, a renowned phosphate binder, has seen a considerable hike. The US, being the advanced healthcare market and innovation hub, dominates the region with increased acceptance of preventive healthcare and Medicare services, which promote the use of SEVELAMER HYDROCHLORIDE tablet. Nonetheless, the market here faces stiff competition, primarily owing to the existence of other established phosphate binders and novel therapeutics in kidney care.

Asia Pacific Outlook

The Asia Pacific region is an emerging market for SEVELAMER HYDROCHLORIDE tablet. With large untapped demographic advantage and expanding healthcare facilities, countries like India and China are driving the demand for these tablets. The battle against chronic kidney diseases amidst a population well above 1 billion is further bolstering opportunities for the SEVELAMER HYDROCHLORIDE market. The region lags due to the underdeveloped healthcare infrastructure and challenges over affordability.

Growth Opportunities in North America and Asia Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., China, Japan, Germany, Australia are expected to grow at 4.2% to 6.1% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 7.4% to 8.8% CAGR

Market Analysis Chart

The widespread prevalence of kidney diseases gives a significant push to the demand for SEVELAMER HYDROCHLORIDE tablets in the pharmaceutical industry. The chronic nature of these ailments necessitates long-term medication, contributing to a substantial market growth for SEVELAMER HYDROCHLORIDE. Furthermore, the tablets efficiency in controlling high blood phosphate levels is bolstering its use.

Recent Developments and Technological Advancement

December 2024

Pharmaceutical major Merck Sharp & Dohme Corp. launched a new formulation of its SEVELAMER HYDROCHLORIDE tablet, strengthening its market position.

October 2024

AstraZeneca secured FDA approval for a generic version of their SEVELAMER HYDROCHLORIDE tablet, providing a more affordable option for patients.

September 2024

Novartis introduced a higher dosage variant of their SEVELAMER HYDROCHLORIDE tablet to cater to the specific needs of kidney patients.

The SEVELAMER HYDROCHLORIDE tablet, primarily used to control increased levels of phosphorus in people who are on dialysis due to severe kidney disease, is experiencing noteworthy market developments in recent times. A notable trend pertains to the increase in generic drug usage, given their cost-effectiveness and equivalent effectiveness to their branded counterparts.

Impact of Industry Transitions on the Sevelamer Hydrochloride Tablet Market

As a core segment of the Pharmaceutical industry, the Sevelamer Hydrochloride Tablet market develops in line with broader industry shifts. Over recent years, transitions such as Expansion Into Emerging Markets and Innovation Through Research and Development have redefined priorities across the Pharmaceutical sector, influencing how the Sevelamer Hydrochloride Tablet market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Expansion Into Emerging Markets:

Sevelamer Hydrochloride tablet, being a highly effective phosphate binder, is experiencing increased demand in developing countries. This is propelled by the escalating prevalence of kidney diseases and unmet medical needs in these regions, underpinned by lifestyle changes and an aging population. For instance, pharmaceutical companies are tapping into this growing demand by extending their supply chains and devising strategic partnerships with local distributors, subsequently leading to an augmented presence in these markets. This transition is not only fueling the growth for the Sevelamer Hydrochloride tablet industry but is also impacting associated industries like distribution and logistics, driving them towards innovation and technological advancements to meet the increased demand and ensure smooth supply chains.

2

Innovation Through Research and Development:

Another significant industry transition is the increased research and development activities around Sevelamer Hydrochloride tablets. Pharmaceutical companies are investing heavily in R&D to improve the effectiveness and reduce potential side effects of this medication.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Sevelamer Hydrochloride Tablet market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Kidney Disorders, and Technological Advancements In Drug Production

The increasing occurrences of kidney issues have also led to a need for Sevelamer Hydrochloride tablets as a treatment option for chronic kidney disease . These tablets are also known for their effectiveness in lowering elevated phosphate levels in individuals with kidney conditions by binding to dietary phosphate and assisting in its removal, from the body. Thereby playing a key role in effectively managing CKD.
There have also been significant technological advancements in the pharmaceutical industry. High-tech machinery and innovative processes have also made it easier, quicker, and more cost-effective to produce Sevelamer Hydrochloride tablets. With improved accessibility and affordability, the Sevelamer Hydrochloride tablet market shows promising potential.
The growing recognition of the significance of regulating phosphate levels in the body has also led to an increased awareness of viable treatment solutions among individuals today. This shift in perspective has also propelled the Sevelamer Hydrochloride tablet into prominence as a leading option for managing phosphate levels in individuals suffering from kidney ailments. Governments and healthcare institutions across the globe are also placing an emphasis on educating patients about these beneficial treatment choices to foster a consistent and optimistic progress for the Sevelamer Hydrochloride tablet, in the healthcare landscape.

Restraint: High Cost of Treatment

The SEVELAMER HYDROCHLORIDE pill is prescribed to manage phosphorus levels in individuals undergoing dialysis due to chronic kidney disease; however it comes with a substantial financial burden for patients seeking treatment with this medication. The significant cost could potentially hinder the markets growth by restricting access for individuals in less developed and underprivileged areas. The challenge of patients being unable to afford the medication poses an obstacle in the market, for SEVELAMER HYDROCHLOIRDE tablets which affects its expansion and progress significantly.

Challenge: Adverse Side Effects

The potential side effects of SEVELAMER HYDROCHLORIDE tablets, such as nausea, vomiting, diarrhea, and stomach pain, might also serve as a considerable on its market growth. Although these symptoms are generally mild and manageable, their presence can discourage patients from adhering to treatment regimens.

Supply Chain Landscape

Raw Material Acquisition

BASF SE

Dow Inc

API Production

Dr. Reddy's Laboratories

Aurobindo Pharma

Tablet Formulation
Sun Pharmaceutical Industries / Cipla Ltd
Distribution & Retail
CVS Health / Walgreens Boots Alliance
Raw Material Acquisition

BASF SE

Dow Inc

API Production

Dr. Reddy's Laboratories

Aurobindo Pharma

Tablet Formulation

Sun Pharmaceutical Industries

Cipla Ltd

Distribution & Retail

CVS Health

Walgreens Boots Alliance

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Chronic Kidney Disease (CKD)
Healthcare & Pharmaceuticals
Sanofi
Focusing on effective marketing of Renagel, a SEVELAMER HYDROCHLORIDE tablet, through customer-centric and targeted promotional strategies
End-stage Renal Disease (ESRD)
Healthcare & Pharmaceuticals
Fresenius Medical Care
Providing cost-effective and high-quality SEVELAMER HYDROCHLORIDE tablets in its expansive dialysis service centers to enhance patient care
Hyperphosphatemia
Healthcare & Pharmaceuticals
Dr. Reddy's Laboratories
Striving for market growth by expanding its generic SEVELAMER HYDROCHLORIDE tablet portfolio to cater to diverse demographic groups across the globe
Post-surgical Phosphate Management
Healthcare & Pharmaceuticals
Hikma Pharmaceuticals
Leveraging robust R&D capabilities and strategic alliances to strengthen the market positioning of its SEVELAMER HYDROCHLORIDE tablet offerings

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Sevelamer Hydrochloride Tablet market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Sevelamer Hydrochloride Tablet in Management of Hyperphosphatemia, Medical Treatment for Chronic Kidney Disease (CKD) and Dialysis Treatment

Management of Hyperphosphatemia

In the sphere of hyperphosphatemia management, Sevelamer Hydrochloride tablets serve as an effective treatment. They function by binding the dietary phosphorus in the gut and reducing its absorption in the bloodstream, thus controlling high phosphorus level conditions, hyperphosphatemia.

Medical Treatment for Chronic Kidney Disease (CKD)

Sevelamer Hydrochloride tablets are primarily used in the medical sector for treating patients with Chronic Kidney Disease.These tablets can help regulate the levels of phosphorus in CKD patients blood, which is crucial for maintaining bone strength and preventing heart ailments. Sevelamer Hydrochloride tablets, namely RenaGel and Renvela, are prescribed in major healthcare institutions worldwide due to their efficacy and reduced side effects compared to other phosphate binders.

Dialysis Treatment

Sevelamer Hydrochloride tablet plays a pivotal role in the dialysis process, particularly in haemodialysis, where it effectively controls the phosphate levels in the blood. Renvela tablets, a variant of Sevelamer Hydrochloride, are commonly used by healthcare professionals in this application due to their optimal binding capabilities that check hyperphosphatemia, common in patients undergoing dialysis treatment. Top nephrology institutions and dialysis centres prefer this tablet because of its consistent performance and tolerability.

Sevelamer Hydrochloride Tablet vs. Substitutes:
Performance and Positioning Analysis

While alternatives like calcium acetate capture phosphates in the gut, SEVELAMER HYDROCHLORIDE tablets outperform by also maintaining lipid profiles stability. Its unique market position promises potential growth due to the increased prevalence of kidney ailments

Sevelamer Hydrochloride Tablet
  • "Calcium Carbonate tablets /
  • Lanthanum Carbonate oral powder
    Effective in lowering phosphate levels, Improves overall kidney function
    May cause gastrointestinal issues, High cost
    Enhanced effectiveness, slightly lower pricing
    high risk of side effects, complex dosing guidelines

Sevelamer Hydrochloride Tablet vs. Substitutes:
Performance and Positioning Analysis

Sevelamer Hydrochloride Tablet

  • Effective in lowering phosphate levels, Improves overall kidney function
  • May cause gastrointestinal issues, High cost

"Calcium Carbonate tablets / Lanthanum Carbonate oral powder / Magnesium Hydroxide tablets"

  • Enhanced effectiveness, slightly lower pricing
  • high risk of side effects, complex dosing guidelines

While alternatives like calcium acetate capture phosphates in the gut, SEVELAMER HYDROCHLORIDE tablets outperform by also maintaining lipid profiles stability. Its unique market position promises potential growth due to the increased prevalence of kidney ailments

Loading...

Research Methodology

This market research methodology defines the Sevelamer Hydrochloride Tablet market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Sevelamer Hydrochloride Tablet across {Application Area 1}, {Application Area 2}, and {Application Area 3} Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Sanofi S.A., Fresenius SE & Co., and Mylan N.V. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Acquisition, API Production, and Tablet Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Sevelamer Hydrochloride Tablet segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Acquisition (BASF SE, Dow Inc), API Production (Dr. Reddy's Laboratories, Aurobindo Pharma), and Tablet Formulation. Our parallel substitute analysis examines "Calcium Carbonate tablets, Lanthanum Carbonate oral powder, and Magnesium Hydroxide tablets", highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Sanofi S.A., Fresenius SE & Co., and Mylan N.V., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Sevelamer Hydrochloride Tablet market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Sevelamer Hydrochloride Tablet Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 1.03 billion
Revenue Forecast in 2034USD 1.80 billion
Growth RateCAGR of 6.4% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024965 million
Growth OpportunityUSD 830 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024965 million USD
Market Size 20271.16 billion USD
Market Size 20291.32 billion USD
Market Size 20301.40 billion USD
Market Size 20341.80 billion USD
Market Size 20351.91 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDosage Form, End-Use Industries, Therapy Area, Prescription Category, Distribution Channels
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledSanofi S.A., Fresenius SE & Co., Mylan N.V., Lupin Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Zydus Cadila, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Teva Pharmaceutical Industries Ltd. and Alembic Pharmaceuticals Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Sevelamer Hydrochloride Tablet Market Size, Opportunities & Strategic Insights, by Dosage Form

4.1Capsule
4.2Liquid
Chapter 5

Sevelamer Hydrochloride Tablet Market Size, Opportunities & Strategic Insights, by End-Use Industries

5.1Healthcare Providers
5.2Retail Pharmacies
5.3Online Pharmacies
5.4Geriatric Care Centers
5.5Chronic Kidney Disease Clinics
5.6Others
Chapter 6

Sevelamer Hydrochloride Tablet Market Size, Opportunities & Strategic Insights, by Therapy Area

6.1Hyperphosphatemia
6.2Chronic Kidney Disease
6.3Dialysis Patients
Chapter 7

Sevelamer Hydrochloride Tablet Market Size, Opportunities & Strategic Insights, by Prescription Category

7.1Over-the-counter
7.2Prescription-based
Chapter 8

Sevelamer Hydrochloride Tablet Market Size, Opportunities & Strategic Insights, by Distribution Channels

8.1Hospital Pharmacies
8.2Retail Pharmacies
8.3Online Pharmacies
8.4Long-Term Care Facilities
Chapter 9

Sevelamer Hydrochloride Tablet Market, by Region

9.1North America Sevelamer Hydrochloride Tablet Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Sevelamer Hydrochloride Tablet Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Sevelamer Hydrochloride Tablet Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Sevelamer Hydrochloride Tablet Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Sevelamer Hydrochloride Tablet Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Sevelamer Hydrochloride Tablet Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Sanofi S.A.
10.2.2Fresenius SE & Co.
10.2.3Mylan N.V.
10.2.4Lupin Ltd.
10.2.5Torrent Pharmaceuticals Ltd.
10.2.6Dr. Reddy's Laboratories Ltd.
10.2.7Cipla Ltd.
10.2.8Zydus Cadila
10.2.9Sun Pharmaceutical Industries Ltd.
10.2.10Aurobindo Pharma
10.2.11Teva Pharmaceutical Industries Ltd.
10.2.12Alembic Pharmaceuticals Ltd.